Trazodone/Fluconazole (Less Than or Equal to 150 mg) Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Your medicine may slow down how quickly your liver processes trazodone.

What might happen:

The amount of trazodone in your blood may increase and cause side effects such as nausea, dizziness, confusion, low blood pressure, fainting, or an irregular heartbeat, which may be life-threatening.High serotonin levels may cause changes in body temperature, blood pressure, and behavior or mood, leading to a medical condition called Serotonin Syndrome. Serotonin Syndrome may be life threatening.

What you should do about this interaction:

Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together and contact your doctor right away if you have an increase in nausea, confusion, or low blood pressure, or if you have any dizziness, fainting, or an irregular heartbeat, or muscle twitching, tremors, shivering, muscle stiffness, fever, heavy sweating, heart palpitation, restlessness, confusion, agitation, trouble with coordination, or severe diarrhea. Your doctor may want to change the dose of your trazodone.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Oleptro (trazodone hydrochloride) US prescribing information. Angelini Labopharm Inc. November, 2012.
  • 2.Diflucan (fluconazole) US prescribing information. Pfizer Inc. January, 2023.
  • 3.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
  • 4.Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol 2005 Oct;45(10):1187-97.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.